Highly Active Antiretroviral Treatment Initiated Early in the Course of Symptomatic Primary HIV‐1 Infection: Results of the ANRS 053 Trial

Open Access
Publisher Website
Google Scholar
Abstract
Highly active antiretroviral treatment (HAART) was given early to 64 patients with symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of analysis, patients had been followed up for 9–21 months. No patient had died or developed an AIDS-defining event. Survival analysis showed that by month 21 the proportion of patients with plasma HIV-1 RNA μL. These preliminary results support the use of HAART in patients with primary HIV-1 infection.

This publication has 0 references indexed in Scilit: